NEW YORK CITY, NY / ACCESS Newswire / November 11, 2026 / Zura Bio Limited (NASDAQ: ZURA) shares fell approximately 72% at the market open on November 9, 2026 after the Company announced that its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa did not meet its primary endpoint at either dose tested. If you bought ZURA and watched your shares lose more than two-thirds of their value, you may have legal rights. Investors who suffered losses are encouraged to submit your ZURA loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Tibulizumab is Zura's lead product candidate. The TibuSHIELD trial completed enrollment with 247 participants. Its primary endpoint was the percent change from baseline in total abscess and inflammatory nodule count at Week 16. Neither dose met that endpoint, and key secondary endpoints were also missed.

Zura has discontinued development of tibulizumab for hidradenitis suppurativa. Levi & Korsinsky is investigating potential securities law violations on behalf of ZURA shareholders who lost money in the decline.

Lost money on Zura Bio? Request a free review of your ZURA losses or call (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured billions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the ZURA Investigation

Q: Who is conducting the ZURA investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased ZURA securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered billions of dollars for aggrieved investors.

Q: Who is eligible to participate in the ZURA investigation? A: Investors who purchased ZURA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did ZURA stock drop? A: Shares fell approximately 72% at the market open on November 9, 2026 after the Company disclosed that its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa did not meet its Week 16 primary endpoint and that it was discontinuing development in that indication. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: What do ZURA investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my ZURA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ZURA and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP